MORE►
biotechnology
Early-stage oncology companies will have the opportunity to compete for lab and office space at BioLabs Pegasus Park, a $25,000 cash prize, and invaluable guidance from industry professionals. [Photo: BioLabs at Pegasus Park]
Secretome Therapeutics Closes $20.4M Financing Round to Advance Heart Therapies
by Lance Murray | Dec 9, 2024
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
by Quincy Preston |
Aug 9, 2024
With a new CEO and three seasoned industry veterans joining its board, Research Bridge Partners is focused on moving university innovations from the lab to the marketplace.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
MORE►
by Nicole Ward, DRC Data Journalist |
Aug 1, 2024
OncoNano's innovative approach to cancer treatment leverages nanotechnology to bring tumors into the light.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
Secretome Therapeutics Appoints Financial Veteran as CFO
by Lance Murray | Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
by Lance Murray |
Jun 14, 2023
The alliance's first event will be held June 22 in a bid to champion a next-generation, industry-led workforce partnership for North Texas. The alliance seeks to bring together industry trade and manufacturing ecosystems, the organizations said—and it will be working with Dallas College and other partner institutions to help make it happen.
MORE►
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
by Lance Murray |
Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE►
Photo illustration sources: ClaudioVentrella/iStock, Michael Samples
Bio Boom: Dallas-Fort Worth Is Emerging as a Hub for Biotech and Life Sciences
by Mike Rosa | Nov 27, 2020
Biotechnology is alive and growing in DFW. The region recently ranked 6th on a list of top ten emerging life science clusters in the U.S.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Quincy Preston |
Oct 8, 2020
This year's Nobel Prize in Chemistry, awarded to two female scientists for the development of CRISPR as a gene-editing tool, is a revolution, according to a pair of UTSW scientists.
UTSW's Eric Olson and Rhonda Bassel-Duby use the technology in their work to treat Duchenne muscular dystrophy. Olson also is the co-founder of biotech Exonics Therapeutics, which exited last year in a deal roughly valued at $1B.
MORE►
by Alex Edwards |
Sep 22, 2020
CEO Brandom Gengelbach says he’s doing business differently in the fast-growing city “where the West begins.”
MORE►
Marketing image for one of Eyevance Pharmaceuticals' products, Flarex. [eyevance.com]
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by Alex Edwards | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
by Quincy Preston |
Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
by Quincy Preston |
Aug 20, 2020
OncoNano Medicine, a spinout of University of Texas Southwestern, uses pH as a biomarker to detect metastatic cancer. Its technology, which visualizes a tumor, could be a gamechanger.
MORE►
by Alex Edwards |
Jul 13, 2020
CAGE Bio—currently a resident at Johnson & Johnson Innovation—uses a proprietary platform to develop therapeutic products for dermatology, inflammation, and immunology.
MORE►
